Theriva Biologics (TOVX) Stock Analysis

What Theriva Biologics does

Theriva Biologics Inc. is a clinical-stage biotechnology firm dedicated to developing novel treatments for conditions with significant unmet medical needs. The company's pipeline features several promising candidates, including SYN-004, which is engineered to break down commonly used intravenous beta-lactam antibiotics in the gastrointestinal tract. This degradation aims to avert microbiome damage, Clostridioides difficile infection (CDI), the overgrowth of harmful organisms, the rise of antimicrobial resistance (AMR), and acute graft-versus-host disease (aGVHD) in patients undergoing allogeneic hematopoietic cell transplants. Another key investigational therapy is SYN-020, an orally administered recombinant formulation of intestinal alkaline phosphatase, designed to address both localized gastrointestinal and systemic diseases. Additionally, Theriva Biologics is advancing VCN-01 for the treatment of various cancers, specifically pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. Its broader clinical-stage portfolio includes SYN-006, intended to prevent aGVHD and infections caused by carbapenem-resistant enterococci; SYN-007, aimed at preventing antibiotic-associated diarrhea linked to oral beta-lactam antibiotics; SYN-005, for both the prevention and treatment of pertussis; and VCN-11, another cancer-focused therapy. The company collaborates with institutions such as Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. Furthermore, a clinical trial agreement with Washington University School of Medicine in St. Louis is in place to conduct a Phase 1b/2a clinical trial for SYN-004. Formerly known as Synthetic Biologics, Inc., the company rebranded as Theriva Biologics Inc. in October 2022 and is headquartered in Rockville, Maryland.

Key metrics

ETFs linked to TOVX

Broad-market and Healthcare sector ETFs an investor holding Theriva Biologics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how TOVX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Theriva Biologics?

Theriva Biologics trades under the ticker TOVX on AMEX.

Which exchange is TOVX listed on?

TOVX is listed on AMEX.

What sector does Theriva Biologics operate in?

Theriva Biologics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze TOVX in a portfolio?

PortView shows TOVX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.